Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress
Krystal Biotech, Inc. (NASDAQ: KRYS) reported strong operational progress and financial results for Q3 2021 with a cash position of $362.3 million as of September 30. The company is on track to release top-line data from its pivotal GEM-3 study for Dystrophic Epidermolysis Bullosa (DEB) in 4Q21. Other highlights include completed enrollment in the PEARL-1 study and progress on its second manufacturing facility, expected to be operational in 2022. However, net losses increased to $(15.6 million) for Q3.
- Cash position increased to $362.3 million from $271.3 million since December 2020.
- Pivotal GEM-3 study for B-VEC on track for data release in 4Q21.
- Enrollment completed for Phase 1 proof-of-concept study, PEARL-1.
- Net losses increased to $(15.6 million) in Q3 2021 compared to $(9.6 million) in Q3 2020.
- General and administrative expenses rose significantly to $9.6 million in Q3 2021, up from $4.6 million in Q3 2020.
– Top-line results from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) on track for 4Q21
– Enrollment in Phase 1 proof-of-concept study (PEARL-1 study) to treat aesthetic skin conditions is complete
– Strong balance sheet with September 30, 2021 cash, cash equivalents, and investments of
PITTSBURGH, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today reported financial results and key operational progress updates for the third quarter ending September 30, 2021.
“We’ve had a productive third quarter and the momentum continues to build with topline data expected from the pivotal GEM-3 trial evaluating B-VEC this quarter,” said Krish Krishnan, Chairman and CEO of Krystal Biotech, Inc. “If positive, this will be a significant milestone for patients living with DEB and strong validation of our redosable gene therapy platform. Outside of the B-VEC program, we are on track to open enrollment in our Phase 1 study of KB407 for cystic fibrosis in Australia and deliver Phase 1 proof-of-concept efficacy data for KB301 from our wholly-owned subsidiary, Jeune Aesthetics in early 2022. As we continue to advance and grow our pipeline, we are also expanding our manufacturing footprint with continued progress on our second facility – ASTRA – which we expect will come online in 2022.”
Program Highlights & Upcoming Events:
B-VEC for DEB
- The Company recently announced completion of the pivotal GEM-3 trial of topical B-VEC for the treatment of DEB, and expects topline data in the fourth quarter of 2021. Details of the pivotal Phase 3 study can be found at www.clinicaltrials.gov under NCT identifier NCT04491604.
- Enrollment of DEB patients into the open label extension (“OLE”) study, including patients who participated in the Phase 3 study as well as new participants who were unable to participate in the Phase 3 study who meet all enrollment criteria, is ongoing. Details of the OLE study can be found at www.clinicaltrials.gov under NCT identifier NCT04917874.
KB407 for Cystic Fibrosis
- More detailed results from the Good Laboratory Practice toxicology and biodistribution study were presented in a poster at the virtual 2021 North American Cystic Fibrosis (“CF”) Conference that took place November 2-5.
- Krystal expects to initiate a Phase 1 clinical trial of inhaled KB407 in patients with CF in Australia in the fourth quarter of 2021 following the announcement that the Bellberry Human Research Ethics Committee granted approval to conduct the study. The Company plans to initiate a clinical trial of KB407 in patients with CF in the U.S. in 2022.
KB105 for TGM1-ARCI
- Dosing in the next cohort in the ongoing Phase 2 clinical trial of KB105 for the treatment of TGM1-deficient autosomal recessive congenital ichthyosis ("TGM1-ARCI") is on track to resume in 2022.
KB301 for Aesthetic Indications
- Jeune Aesthetics, Inc. (“Jeune”), the Company’s wholly-owned subsidiary, is currently conducting a Phase 1 proof-of-concept study of intradermal KB301, designed to deliver the human COL3A1 gene to enable increased endogenous production of type III collagen. Details of the study can be found at www.clinicaltrials.gov under NCT identifier NCT04540900.
- Enrollment in the second cohort is complete and Jeune expects to announce initial data, including efficacy data, in early 2022.
- Jeune will present results from in vitro and in vivo proof-of-concept studies for KB303, the company’s preclinical pipeline candidate designed to enable the targeted delivery of human elastin as a novel therapeutic option to improve skin elasticity at the upcoming virtual American Society for Dermatologic Surgery 2021 meeting, being held on November 19-21.
KB104 for Netherton Syndrome
- The Company continues to work towards an IND filing, which is anticipated in 2022.
Corporate Highlights:
- In September 2021, the Company announced the appointment of Laurent Goux as the General Manager of Europe. Mr. Goux has more than 20 years of global biotechnology experience, including serving as the Head of Global Strategic Marketing and Market Access at Galderma.
- In October 2021, the Company announced the launch of a no-charge genetic testing program for all types of Epidermolysis Bullosa (“EB”). The goal of the program, called Krystal Decode DEBTM, is to help patients with the dystrophic form of this genetic condition, also known as DEB, get a definitive diagnosis sooner, with highly accurate results obtained with a blood or cheek swab sample.
Financial results for the quarter ended September 30, 2021:
- Cash, cash equivalents, and investments totaled
$362.3 million on September 30, 2021, compared to$271.3 million as of December 31, 2020. - Research and development expenses for the third quarter ended September 30, 2021 were
$6.1 million , compared to$5.1 million for the third quarter 2020, and$18.9 million for the nine months ended September 30, 2021, compared to$12.3 million for the nine months ended September 30, 2020. - General and administrative expenses for the third quarter ended September 30, 2021 were
$9.6 million , compared to$4.6 million for third quarter 2020, and$27.5 million for the nine months ended September 30, 2021, compared to$10.3 million for the nine months ended September 30, 2020. - Net losses for the quarters ended September 30, 2021 and 2020 were
$15.6 million and$9.6 million , or$(0.70) and$(0.49) , respectively, per common share (basic and diluted). Net losses for the nine months ended September 30, 2021 and 2020 were$47.8 million and$21.8 million or$(2.18) and$(1.18) , respectively, per common share (basic and diluted). - For additional information on the Company’s financial results for the third quarter ended September 30, 2021, refer to form 10-Q filed with the U.S. Securities and Exchange Commission.
About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ:KRYS) is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases. For more information please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and Twitter.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., including but not limited to statements about the development of Krystal’s product candidates, and the expected timing for ASTRA coming online; and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or trials will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of product candidates, the sufficiency of cash resources and need for additional financing and such other important factors as are set forth under the caption “Risk Factors” in Krystal’s annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal’s views as of the date of this release. Krystal anticipates that subsequent events and developments will cause its views to change. However, while Krystal may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal’s views as of any date subsequent to the date of this release.
CONTACTS:
Investors:
Whitney Ijem
Krystal Biotech
wijem@krystalbio.com
Media:
Julie Normant
Real Chemistry
jnormart@realchemistry.com
Consolidated Balance Sheet Data:
| (In thousands) | September 30, 2021 | December 31, 2020 | ||||||
| Balance sheet data: | ||||||||
| Cash and cash equivalents | $ | 286,614 | $ | 268,269 | ||||
| Working capital | 310,033 | 259,606 | ||||||
| Total assets | 451,095 | 310,844 | ||||||
| Total liabilities | 42,858 | 18,760 | ||||||
| Total stockholders’ equity | $ | 408,237 | $ | 292,084 | ||||
Consolidated Statement of Operations:
| Three Months Ended September 30, | |||||||||||
| (In thousands, except shares and per share data) | 2021 | 2020 | Change | ||||||||
| Expenses | |||||||||||
| Research and development | $ | 6,080 | $ | 5,100 | $ | 980 | |||||
| General and administrative | 9,572 | 4,580 | 4,992 | ||||||||
| Total operating expenses | 15,652 | 9,680 | 5,972 | ||||||||
| Loss from operations | (15,652 | ) | (9,680 | ) | (5,972 | ) | |||||
| Other Income (Expense) | |||||||||||
| Interest and other income, net | 63 | 70 | (7 | ) | |||||||
| Total other income (expense) | 63 | 70 | (7 | ) | |||||||
| Net loss | $ | (15,589 | ) | $ | (9,610 | ) | $ | (5,979 | ) | ||
| Net loss per common share: Basic and diluted | $ | (0.70 | ) | $ | (0.49 | ) | |||||
| Weighted-average common shares outstanding: Basic and diluted | 22,212,266 | 19,676,016 | |||||||||
| Nine Months Ended September 30, | |||||||||||
| (In thousands, except shares and per share data) | 2021 | 2020 | Change | ||||||||
| Expenses | |||||||||||
| Research and development | $ | 18,875 | $ | 12,264 | $ | 6,611 | |||||
| General and administrative | 27,524 | 10,315 | 17,209 | ||||||||
| Total operating expenses | 46,399 | 22,579 | 23,820 | ||||||||
| Loss from operations | (46,399 | ) | (22,579 | ) | (23,820 | ) | |||||
| Other Income (Expense) | |||||||||||
| Interest and other income, net | 127 | 795 | (668 | ) | |||||||
| Build to suit interest expense | (1,492 | ) | — | (1,492 | ) | ||||||
| Total other income (expense) | (1,365 | ) | 795 | (2,160 | ) | ||||||
| Net loss | $ | (47,764 | ) | $ | (21,784 | ) | $ | (25,980 | ) | ||
| Net loss per common share: Basic and diluted | $ | (2.18 | ) | $ | (1.18 | ) | |||||
| Weighted-average common shares outstanding: Basic and diluted | 21,893,656 | 18,477,495 | |||||||||
Source: Krystal Biotech, Inc.
FAQ
What are the top-line results from the GEM-3 study for KRYS?
What financial position does Krystal Biotech have as of September 30, 2021?
What were the net losses for Krystal Biotech in Q3 2021?
What is the purpose of the PEARL-1 study for KRYS?
How have the general and administrative expenses changed for KRYS in Q3 2021?
